In the CAPability-01 trial, chidamide plus a PD-1 inhibitor with or without anti-VEGF monoclonal antibody showed that mPFS was 3.7 months and mOS was not mature in patients with unresectable chemotherapy-refractory locally advanced or metastatic MSS/pMMR CRC (16). This evidence concerns the gene VEGFA and colorectal carcinoma.